20cm速递｜科创创业ETF（588360）涨超1.3%，创新药与器械赛道政策利好受关注

Group 1 - The Smart Medical Insurance Competition reflects the government's supportive attitude towards the development of innovative drugs, with open medical insurance data significantly enhancing the efficiency of drug research and development [1] - Medical insurance data covers a large population and offers rich dimensions, providing substantial real-world data support for innovative drug development, helping teams accurately target clinical needs and determine research directions, thereby shortening development cycles and reducing costs [1] - The competition promotes cross-industry resource integration among pharmaceutical companies, technology firms, and research institutions, potentially leading to new research models and technologies that accelerate the transition of innovative drugs from the lab to clinical application [1] Group 2 - The innovative drug sector has high growth potential and investment value, as approved innovative drugs can achieve significant market share and pricing power due to their clinical advantages, resulting in substantial profit returns for companies [1] - The Science and Technology Innovation and Entrepreneurship ETF (588360) tracks the Science and Technology Innovation 50 Index (931643), which can experience daily fluctuations of up to 20%, reflecting the overall performance of 50 large-cap, liquid securities selected from the Science and Technology Innovation Board and the Growth Enterprise Market [1] - The index covers multiple high-growth industries, including information technology, healthcare, and new energy, focusing on publicly listed companies with strong innovation-driven growth [1]